Centessa Looks To Transform Drug Development With ‘Asset Centric’ Model
Company Bags $250m In Series A
Executive Summary
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
You may also be interested in...
In Vivo’s Deals Of The Year 2021: Cast Your Vote!
It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Finance Watch: Three Newly Public Companies Face Mixed Reception In Early Trading
Also, two more health care-focused SPACs went public, Centessa obtained up to $300m in debt, three new venture capital funds launched and Intergalactic debuted with a $75m series A round.
Finance Watch: Janux Offering Makes 47 Biopharma IPOs In 2021, So Far
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.